Eli Lilly and Co

Change company Symbol lookup

Select an option...

LLY Eli Lilly and Co

FNMA Federal National Mortgage Association

MPW Medical Properties Trust Inc

PSXP Phillips 66 Partners LP

EQ Equillium Inc

TSLA Tesla Inc

OPK OPKO Health Inc

PNW Pinnacle West Capital Corp

ROLL RBC Bearings Inc

GLAD Gladstone Capital Corp

Go

Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT(R)) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. The...(PR Newswire)

The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) - a neutralizing antibody - in the...(PR Newswire)

Eli Lilly and Company (NYSE: LLY) announced today an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing antibody, for $375 million. The U.S. government will accept...(PR Newswire)

Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2020. Certain financial information for 2020 and 2019 is presented on both a reported and a non-GAAP basis. Some numbers in this press release may not add...(PR Newswire)

MBX Biosciences, a drug discovery company focused in rare endocrine diseases, today announced the appointment of James Cornelius to its board of directors. "Jim Cornelius is among the most accomplished global biopharmaceutical executives, and he is...(BusinessWire)

Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. (Globe Newswire)

Findings from a new exploratory sub-analysis of the EMPEROR-Reduced phase III trial showed that Jardiance(R) (empagliflozin) reduced the risk of adverse cardiovascular and kidney events in adults with heart failure with reduced ejection fraction...(PR Newswire)

Enormous amounts of money exchange hands in the big pharma space as companies merge and are acquired -- all in search of the next blockbuster drug. While the discovery of a blockbuster drug, or a drug that generates more than $1 billion in sales per...(PR Newswire)

Los Angeles, California--(Newsfile Corp. - October 21, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or "the...(Newsfile)

Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. (PR Newswire)

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders. Our investigation concerns whether Eli Lilly has...(Globe Newswire)

The Law Offices of Frank R. Cruz continues its investigation of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY) on behalf of investors concerning the Company's possible violations of federal securities laws. (BusinessWire)

Research continues to mount on the health benefits of psychedelic drugs like psilocybin and loosening government restrictions are completely changing the way the world views psychedelics. What was once reserved for teenagers tripping out in their...(PR Newswire)

The 5th Annual Companion Diagnostics Forum will take place Tuesday and Wednesday, October 27-28, 2020. Register at http://companiondiagnosticsforum.com. "The online Companion Diagnostics Forum is focused on the need for Companion Diagnostics to grow...(PR Newswire)

Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, continues its investigation on behalf of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY) investors concerning the Company's possible violations...(BusinessWire)

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable December 10, 2020, to shareholders of record at the close of...(PR Newswire)

New York, New York--(Newsfile Corp. - October 18, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Eli Lilly and Company ("Eli Lilly" or the...(Newsfile)

Los Angeles, California--(Newsfile Corp. - October 16, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or "the...(Newsfile)

New York, New York--(Newsfile Corp. - October 15, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Eli Lilly and Company ("Eli Lilly" or the...(Newsfile)

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company (NYSE: LLY) on behalf of Eli Lilly stockholders. Our investigation concerns whether Eli Lilly has...(Globe Newswire)